@prefix nkg: .
@prefix nt: .
@prefix orcid: .
@prefix bl: .
@prefix this: .
@prefix sub: .
@prefix np: .
@prefix rdf: .
@prefix xsd: .
@prefix rdfs: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubInfo;
a np:Nanopublication .
}
sub:assertion {
a bl:Disease .
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "Similarly, De Cos Milas et al. [6] described their clinical experience with paliperidone in adolescents. They presented 3 males and 2 females, age between 15 and 17 years. Diagnoses were autism, borderline personality disorder, schizotypal personality disorder, personality disorder not otherwise specified, and schizophrenia. Prescribed dose was 3–9 mg/day, and actual mean time of treatment duration is 5.8 months. In 4 cases, paliperidone was initiated as a change from other antipsychotic. There were no adverse effects that required discontinuation and in all cases symptoms improved.";
bl:has_population_context sub:context;
bl:provided_by ;
bl:publications ;
bl:relation nkg:OffLabelIndication .
sub:context a bl:Cohort;
rdfs:label "Adolescents (15-17)" .
a bl:Drug .
}
sub:provenance {
sub:assertion prov:generatedAtTime "2021-08-24T16:13:47.586648"^^xsd:dateTime .
}
sub:pubInfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB";
npx:hasSignature "GqT07hBN6al0Vf9zMLUZYNzBCP2WgoGtVEi1VIIjzx7DszQkCsPChUxAeFYXFkkJTi/Z/qgmVFi2SvV79CLKc13RJvQXvBfyFBBGGGCFmfnKTMBESghqW8/+WwQLkPz6tOUzfoJxKW5+LWXCcq5p2gN+XVWWYcOk9CFa/O50QMs=";
npx:hasSignatureTarget this: .
this: prov:generatedAtTime "2021-08-24T16:13:47.586648"^^xsd:dateTime;
prov:wasAttributedTo orcid:0000-0002-7641-6446;
nt:wasCreatedFromTemplate .
}